Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P920047/S138

RHYTHMIA HDx Ablation Connection Box (for INTELLAGEN) (M004RA65010)

Boston Scientific Corp · Decision date Oct 17, 2025

FDA DECISIONP920047/S138

What did the FDA decide?

FDA records P920047/S138 as a supplement to PMA P920047, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 17, 2025.

FDA approval order statement

the addition of a new soldering machine at a supplier
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 17, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P920047/S138
Regulatory pathway
PMA supplement
Product code
LPB
Decision code
OK30
Decision date
Oct 17, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cardiac ablation percutaneous catheter.

Product code
LPB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P920047/S137 · Related supplement

    Blazer II Cardiac Ablation System and Cable

  2. P920047/S138 received

    Application receipt date recorded by FDA.

  3. P920047/S138 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P920047. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P920047

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA supplementAug 14, 2025FDA

Explore the linked device profile

Other records with product code LPB

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
Irvine Biomedical, Inc.PMA supplementSep 3, 2026FDA
Ampere GeneratorP040014/S051
Irvine Biomedical, Inc.PMA supplementAug 7, 2026FDA
Ampere GeneratorP960016/S094
St Jude MedicalPMA supplementAug 7, 2026FDA
Stereotaxis, Inc.PMA supplementJul 31, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records